Tesamorelin Dosage: The Complete Protocol Guide (FDA Data + Clinical Research)

Tesamorelin Dosage: The Complete Protocol Guide (FDA Data + Clinical Research)

Important: This article is for educational purposes only. We are not doctors. Nothing here is medical advice. Talk to a qualified healthcare provider before starting any peptide protocol or medication.

---

Key Takeaways

• Tesamorelin (brand name Egrifta) is FDA-approved for one indication only: reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It is a prescription pharmaceutical, not a research compound.
• The FDA-approved tesamorelin dose is 2mg subcutaneous injection once daily into the abdomen.
• Egrifta SV is a newer single-use vial formulation. Egrifta WR delivers equivalent results at 1.28mg once daily due to higher concentration.
• In the LIPO-010 Phase 3 trial, tesamorelin 2mg daily reduced trunk fat by 18% versus placebo over 26 weeks. The full range across both Phase 3 trials was 11.7% to 19.6% visceral fat reduction.
• A 2026 meta-analysis of five RCTs found tesamorelin reduced visceral adipose tissue by a mean of 27.71 cm2 and increased lean body mass by 1.42 kg (Badran et al., 2026).
• Off-label cycling protocols typically follow 60-90 day cycles with 30-day breaks to manage receptor desensitization. This is not FDA-sanctioned.
• Tesamorelin is contraindicated in active malignancy, pregnancy, pituitary axis disruption, and hypersensitivity to its components.
• All legal access requires a physician prescription.

---

What Is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is a 44-amino acid polypeptide with a trans-3-hexadecanoic acid modification at the N-terminal end. That modification improves stability compared to native GHRH.

The FDA approved tesamorelin in November 2010 under the brand name Egrifta, developed by Theratechnologies Inc.

The mechanism is straightforward. Tesamorelin binds to GHRH receptors in the anterior pituitary gland. That binding triggers pulsatile release of endogenous growth hormone. GH then travels to the liver, where it stimulates production of IGF-1 (insulin-like growth factor-1). IGF-1 drives the downstream effects, including lipolysis of visceral adipose tissue.

This is a key distinction from injecting synthetic growth hormone directly. Tesamorelin works through the body's own pituitary feedback system. The pituitary still controls the GH response, which preserves the natural regulatory loop.

Despite a very short half-life of 7 to 13 minutes after injection, tesamorelin produces lasting hormonal effects. A single daily GH pulse is sufficient to sustain elevated IGF-1 levels throughout the day. Studies show IGF-1 reaches measurably elevated steady-state within approximately 2 weeks of daily administration (Dhillon, 2011).

---

The FDA-Approved Tesamorelin Dose

The standard FDA-approved tesamorelin dosage is 2mg administered as a subcutaneous injection once daily.

This dose was established in the Phase 3 clinical trials supporting FDA approval. Injection site: the abdomen. Rotate across different areas of the abdomen with each dose. Do not inject into scar tissue, bruises, or the navel.

The Egrifta WR formulation delivers equivalent clinical outcomes at 1.28mg once daily due to a higher concentration formulation (8mg/mL versus the earlier 1mg/mL). Both options are FDA-approved for the same indication.

What the Phase 3 Trials Showed

Both registration trials that supported FDA approval used the 2mg daily subcutaneous dose in HIV-infected patients with abdominal fat accumulation (lipodystrophy).

The primary endpoint was percent change in visceral adipose tissue (VAT) measured by CT scan at 26 weeks. Results from the NCBI Clinical Review and FDA prescribing label:

• LIPO-010 trial: LS mean difference versus placebo: -19.6% (95% CI: -23.7% to -15.3%). Trunk fat reduction of approximately 18%.
• CTR-1011 trial: LS mean difference versus placebo: -11.7% (95% CI: -16.2% to -7.1%)

A separate JAMA-published trial found tesamorelin 2mg daily over 6 months reduced visceral adipose tissue by a mean of 34 cm2 compared to an 8 cm2 increase in the placebo group. That same study found a relative 40% reduction in liver fat in the tesamorelin group versus a 27% increase in placebo (Stanley et al., 2014).

The original NEJM trial enrolled 412 HIV-infected patients with abdominal fat accumulation over 26 weeks. Beyond visceral fat, it documented improvements in triglycerides, total cholesterol to HDL ratio, and self-assessed body image (Falutz et al., 2007).

2026 Meta-Analysis: Pooled Data From Five RCTs

A 2026 systematic review and meta-analysis pooled data from five randomized controlled trials. The results confirmed what the individual trials showed, but with tighter statistical confidence:

• Visceral adipose tissue: -27.71 cm2 (95% CI: -38.37 to -17.06; P < 0.001)
• Trunk fat: -1.18 kg (95% CI: -1.40 to -0.96; P < 0.001)
• Lean body mass: +1.42 kg (95% CI: 1.13 to 1.71; P < 0.001)
• Hepatic fat: -4.28% (95% CI: -6.31 to -2.24; P < 0.001)
• Waist circumference: -1.61 cm (95% CI: -2.28 to -0.95; P < 0.001)

Notably, there was no significant reduction in subcutaneous adipose tissue or BMI. Tesamorelin targets visceral fat specifically. Total body weight changes are modest (Badran et al., 2026).

---

Tesamorelin Dosage for Fat Loss (Off-Label)

The clinical evidence for tesamorelin and fat loss is specific to visceral fat in HIV-associated lipodystrophy. That is the population with strong randomized controlled trial data.

Off-label use for visceral fat reduction in non-HIV individuals has grown among longevity and functional medicine physicians. This use is not FDA-approved, but the dosing logic follows the same 2mg daily framework.

What "Fat Loss" Actually Means Here

The fat loss is specifically visceral (deep abdominal) fat, not total body weight. Tesamorelin does not produce dramatic scale changes. What it does is reduce the dangerous fat surrounding your organs.

Effects do not persist after stopping. Visceral fat returns toward baseline within weeks of discontinuation. This is not a one-and-done compound.

Off-Label Research Protocols (Non-HIV Populations)

For off-label use in aging or metabolically unhealthy adults without HIV, research protocols documented in clinical practice typically use:

• Dose: 1 to 2mg subcutaneously, once daily
• Timing: Before bed, at least 90 minutes after the last meal
• Cycle: 60 to 90 days on, followed by a 30-day break
• Monitoring: IGF-1 and fasting glucose checked at baseline and 4 to 8 weeks into the cycle

This is not an FDA-approved protocol. Off-label use of a prescription pharmaceutical requires physician supervision. We present this for educational context because published clinical discussions of tesamorelin increasingly include non-HIV populations.

Tesamorelin Dose for Body Recomp

For body recomposition specifically, the 2026 meta-analysis data is relevant. Tesamorelin reduced visceral fat while simultaneously increasing lean body mass by 1.42 kg across pooled trial data. That combination of losing visceral fat and gaining lean tissue is the definition of recomposition.

The Phase 3 responder analysis showed that patients with 8% or greater VAT reduction also experienced improved triglycerides, adiponectin, and glucose homeostasis over 52 weeks of treatment (Stanley et al., 2012).

For body recomp goals, the full 2mg daily dose appears necessary. Lower doses have not been studied for composition-specific endpoints.

---

How to Reconstitute Tesamorelin (Egrifta SV)

Egrifta SV is a single-use vial formulation. It comes as a lyophilized (freeze-dried) powder that must be reconstituted before injection. The following covers the general protocol per the FDA prescribing information. Always follow your specific product label.

What You Need

• Tesamorelin lyophilized powder vial (Egrifta SV single-use)
• Sterile water for injection (provided with Egrifta SV)
• Syringe and needle (provided in the kit)
• Alcohol prep pads
• Clean, flat surface

Step-by-Step Reconstitution

Step 1. Wash your hands. Let the vial reach room temperature. Do not use a microwave or hot water to warm it.

Step 2. Scrub the rubber stopper of the tesamorelin vial with an alcohol prep pad. Let air dry for 5 to 10 seconds.

Step 3. Draw the full amount of sterile water from the diluent syringe. For Egrifta SV, the diluent volume is pre-measured.

Step 4. Insert the needle into the tesamorelin vial at an angle so the water stream runs down the inside glass wall. Do not inject the water directly onto the powder. Forceful contact can shear the peptide bonds and reduce potency.

Step 5. Gently roll the vial between your palms until the powder fully dissolves. Do not shake. Shaking creates bubbles and can denature the peptide. This may take 30 to 60 seconds.

Step 6. Inspect the solution. Reconstituted tesamorelin should be clear and colorless. Do not use if cloudy, discolored, or contains particles.

Step 7. Draw the full reconstituted solution into the syringe. Egrifta SV is single-use. Use immediately after reconstitution. Do not store reconstituted Egrifta SV.

Injection Protocol

Site: Lower abdomen, at least 2 inches from the navel. Both left and right sides work.

Rotation: Rotate injection sites with each dose. Do not inject the same spot repeatedly. This reduces injection site reactions.

Technique: Subcutaneous only (not intramuscular). Pinch a small fold of skin. Insert the needle at 45 to 90 degrees depending on body composition. Inject slowly. Withdraw.

Timing: Most protocols recommend injecting before bed, at least 90 minutes after the last meal. A fasting state at injection time may improve the GH pulse response based on growth hormone physiology. Consistency of timing matters more than the specific time chosen.

For detailed subcutaneous injection guidance applicable to peptide protocols, see our how to reconstitute peptides guide.

---

Tesamorelin Cycle Length and Breaks

FDA-Approved Indication

The FDA label does not specify a maximum cycle length for the approved HIV lipodystrophy indication. The registration trials ran 26 weeks, with responders followed for another 26-week extension. Long-term physician-supervised use is consistent with the approved indication in eligible patients.

The label does specify that patients who do not demonstrate response (assessed by waist circumference or imaging) after a defined period should consider discontinuation.

Off-Label Cycling: 60-90 Days On, 30 Days Off

For off-label use in non-HIV populations, the most common cycling structure is:

Protocol	On Duration	Off Duration	Notes
Standard	60 days	30 days	Most common off-label approach
Extended	90 days	30 days	For patients responding well with good labs
Aggressive	16 to 20 weeks	8 to 12 weeks	Closer to clinical trial durations

The rationale for cycling in off-label use has two parts.

Receptor desensitization. Continuous GHRH receptor stimulation may reduce pituitary responsiveness over time. Taking a 30-day break allows the receptors to resensitize. Published research has not definitively established whether this is clinically significant with tesamorelin specifically, but the theoretical basis is well-documented for GHRH pathway compounds.

Cost management. Tesamorelin is an expensive pharmaceutical. Cycling reduces annual cost by approximately 25% to 33% depending on the protocol.

What Happens During Off-Cycles

Visceral fat begins to return toward baseline during the break period. IGF-1 levels normalize. This is expected. The goal of cycling is to accumulate net fat loss over multiple cycles while managing receptor sensitivity and cost.

Some protocols add lower-cost GH secretagogues like CJC-1295/ipamorelin during the off-cycle to maintain some GH elevation. This is not studied in clinical trials and is purely anecdotal practice.

---

Tesamorelin vs. Other GH Peptides: Dosage Comparison

The table below compares tesamorelin to other commonly researched growth hormone peptides. These compounds are not interchangeable. They have different mechanisms, different evidence levels, and different legal classifications.

Peptide	Class	Standard Research Dose	Frequency	Approx. Half-Life	FDA Approved?
Tesamorelin	GHRH analog	2mg	Once daily	7 to 13 min	Yes (HIV lipodystrophy)
CJC-1295 (no DAC)	GHRH analog	100 to 200mcg	1 to 2x daily	~30 min	No
CJC-1295 (with DAC)	Modified GHRH	1 to 2mg	1 to 2x weekly	~5.8 to 8.1 days	No
Ipamorelin	GHRP / ghrelin agonist	100 to 300mcg	2 to 3x daily	~2 hours	No
AOD-9604	GH fragment (hGH 176-191)	250 to 500mcg	Once daily	~30 min	No

How They Compare

Tesamorelin vs. CJC-1295: Both are GHRH analogs that stimulate pituitary GH release. Tesamorelin has FDA approval and Phase 3 visceral fat reduction data. CJC-1295 has a single published human trial showing dose-dependent GH and IGF-1 increases over 28 to 49 days, but no large-scale fat loss trials (Teichman et al., 2006). CJC-1295 with DAC has the advantage of less frequent dosing (weekly vs. daily). The evidence gap between these two compounds is massive.

Tesamorelin vs. Ipamorelin: Different mechanisms entirely. Tesamorelin stimulates GH release through the GHRH pathway. Ipamorelin stimulates GH release through the ghrelin receptor pathway. They are often stacked together because they hit complementary targets. Ipamorelin's advantage is selectivity. It does not significantly raise cortisol or prolactin. Its disadvantage is no Phase 3 trial data for any indication.

Tesamorelin vs. AOD-9604: AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176-191). It was designed to isolate the fat-burning portion of GH without the growth-promoting effects. Mouse studies showed it reduced body weight and body fat through upregulation of beta-3 adrenergic receptors (Heffernan et al., 2001). A Phase 2a human trial was initiated but AOD-9604 never advanced to Phase 3. The human evidence base is extremely thin compared to tesamorelin. AOD-9604 has no FDA approval and limited published clinical data.

Bottom line: For visceral fat reduction with clinical evidence behind it, tesamorelin sits in a different tier than everything else on this list. For general GH optimization without a specific medical indication, CJC-1295/ipamorelin stacks are more accessible but far less validated. AOD-9604 is the least studied of the group.

---

Tesamorelin Side Effects

Clinical trial data and the FDA prescribing label document the following. These data come primarily from HIV-infected populations at 2mg daily. Side effects at lower off-label doses may differ but have not been systematically studied in large trials.

Common Side Effects (Phase 3 Trial Data)

Injection site reactions. Redness, itching, pain, bruising, and swelling at the injection site. The most frequently reported side effect. Rotating injection sites reduces frequency and severity.

Joint pain (arthralgia) and muscle pain (myalgia). Related to elevated GH and IGF-1. Dose-related. May improve over time or with dose adjustment. The 2026 meta-analysis confirmed arthralgia and myalgia as consistent adverse events across all five pooled trials (Badran et al., 2026).

Peripheral edema. Fluid retention in the extremities, a known effect of elevated GH. Typically resolves without intervention in most patients.

Paresthesia. Tingling or numbness, particularly in the hands and fingers. Also documented in the meta-analysis. Related to fluid retention and nerve compression from GH elevation.

Nausea. Less common but documented in trial populations.

Serious Side Effects Requiring Monitoring

Glucose changes. Growth hormone is diabetogenic. Tesamorelin can increase fasting blood glucose and reduce insulin sensitivity. The prescribing label specifically recommends periodic glucose monitoring. Patients with pre-existing diabetes or insulin resistance need additional oversight.

The pooled meta-analysis data was reassuring here. Across five RCTs, tesamorelin did not produce significant perturbation of glucose homeostasis at the group level. But individual variation exists, and monitoring remains essential.

Elevated IGF-1. Tesamorelin raises IGF-1 levels. The FDA label recommends monitoring IGF-1 during treatment. If levels exceed age- and sex-normalized ranges, dose adjustment or discontinuation should be considered.

Fluid retention with cardiovascular implications. Significant edema can create cardiovascular stress in susceptible individuals.

Hypersensitivity reactions. Allergic reactions including rash, urticaria, and facial flushing have been reported. Serious reactions require immediate discontinuation.

Cancer Risk: What the Data Shows

Tesamorelin elevates GH and IGF-1, both known mitogens (cell growth promoters). This creates a theoretical concern about malignancy risk.

The clinical trial data is mixed. The LIPO-010 trial found a higher percentage of malignancy in the tesamorelin group versus placebo (2.9% vs 1.5%). The CTR-1011 trial found the opposite (0.4% vs 3.2%). As the NCBI Clinical Review notes, trial durations were insufficient to draw firm conclusions about long-term cancer risk.

The FDA prescribing label is explicit: tesamorelin should not be used in patients with active malignancy.

---

Who Should NOT Use Tesamorelin

These are contraindications documented in the FDA prescribing label. This is not an exhaustive list. Any individual decision requires full physician evaluation.

Absolute contraindications:

• Active malignancy (any preexisting malignancy must be inactive with treatment complete before starting)
• Hypersensitivity to tesamorelin, mannitol (used in the formulation), or any component
• Disruption of the hypothalamic-pituitary axis from pituitary tumors, hypophysectomy, head irradiation, head trauma, or hypopituitarism
• Pregnancy

Require caution and active monitoring:

• Diabetes mellitus or pre-diabetes
• History of malignancy (physician must weigh risk vs. benefit)
• Baseline IGF-1 already at the upper range
• Pre-existing significant edema or cardiovascular disease
• Sleep apnea (elevated GH can worsen upper airway obstruction)

Athletes: Tesamorelin is on the World Anti-Doping Agency (WADA) prohibited list as a peptide hormone. Its use is banned in competitive sports.

---

Frequently Asked Questions

How much tesamorelin should I take?

The FDA-approved tesamorelin dose is 2mg subcutaneous injection once daily. The newer Egrifta WR formulation delivers equivalent efficacy at 1.28mg once daily due to a higher-concentration preparation. Both inject into the abdomen with site rotation. Off-label research protocols for non-HIV populations typically follow the same 1 to 2mg daily framework, but require physician supervision and are not FDA-sanctioned.

How long does tesamorelin take to work for fat loss?

IGF-1 levels reach measurably elevated steady-state within approximately 2 weeks of daily administration. Visceral fat changes are typically measurable at 8 to 12 weeks. In the Phase 3 registration trials, statistically significant VAT reductions were documented at 26 weeks with 2mg daily. Most off-label protocols assess response at 8 to 12 weeks minimum before drawing conclusions.

Can tesamorelin be used for fat loss without HIV?

Tesamorelin is not FDA-approved for fat loss outside of HIV-associated lipodystrophy. Off-label use in metabolically healthy or aging individuals is not FDA-sanctioned. Some physicians prescribe it off-label for visceral fat reduction in appropriate patients. Any such use requires a legitimate physician-patient relationship, baseline bloodwork, and ongoing monitoring of IGF-1 and glucose levels.

When should I inject tesamorelin?

The FDA prescribing label specifies once-daily subcutaneous injection but does not mandate a specific time of day. Most clinical protocols and off-label practice recommend injecting before bed, at least 90 minutes after the last meal. A fasting state at injection time may improve the GH pulse response based on growth hormone physiology. Consistency of timing matters more than the specific time.

Does tesamorelin need to be cycled?

The FDA-approved protocol for HIV lipodystrophy does not specify a cycling requirement. The registration trials ran continuously for 26 weeks, with a 26-week extension. Off-label protocols commonly use 60 to 90 days on, followed by a 30-day break. The primary reasons are receptor desensitization management and cost. No published research definitively establishes an optimal cycling protocol for non-HIV populations.

Is tesamorelin the same as Egrifta?

Yes. Egrifta is the brand name for tesamorelin. Egrifta SV is a single-use vial formulation. Egrifta WR is a higher-concentration formulation that delivers equivalent efficacy at 1.28mg instead of 2mg. All are prescription pharmaceuticals manufactured by Theratechnologies Inc.

What is the difference between tesamorelin and CJC-1295?

Both are GHRH analogs that stimulate pituitary growth hormone release. Tesamorelin is FDA-approved with Phase 3 clinical trial data showing visceral fat reduction. CJC-1295 is a research compound with no FDA approval and no large-scale fat loss trials. The evidence gap between these two compounds is significant. Tesamorelin requires a prescription. CJC-1295 is sold through research supply companies.

How does tesamorelin compare to AOD-9604 for fat loss?

Tesamorelin stimulates full growth hormone release through the pituitary. AOD-9604 is a synthetic fragment of growth hormone designed to isolate lipolytic effects. Tesamorelin has two Phase 3 trials and a 2026 meta-analysis supporting its fat reduction claims. AOD-9604 has mouse data and an incomplete Phase 2a program. From an evidence standpoint, the comparison is not close.

---

The Bottom Line

Tesamorelin is the most clinically validated GHRH analog available. Its 2mg daily subcutaneous dosing protocol produced statistically significant visceral fat reductions of 12% to 20% in two Phase 3 trials. A 2026 meta-analysis of five RCTs confirmed a mean visceral fat reduction of 27.71 cm2, a 1.18 kg reduction in trunk fat, and a 1.42 kg increase in lean body mass.

IGF-1 elevation occurs within 2 weeks. Fat loss effects accumulate over 8 to 26 weeks and reverse after stopping.

It carries meaningful contraindications. Active malignancy and pregnancy are absolute. Diabetes and elevated baseline IGF-1 require active monitoring. Anyone with a history of malignancy needs a careful physician-led conversation before considering it.

Off-label use in non-HIV populations follows the same dosing logic (1 to 2mg daily, cycled 60 to 90 days on with 30-day breaks) but without the same evidence base. That use should happen only under physician supervision with monitoring in place.

For anyone researching GH peptides specifically for visceral fat, tesamorelin's clinical evidence sits in a different tier than what exists for CJC-1295, ipamorelin, or AOD-9604. But that evidence does not eliminate the requirement for a legitimate prescription and physician oversight.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research, not medical recommendations.

---

Sources

1. Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PMID: 41545261
2. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357
3. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. DOI: 10.1056/NEJMoa072375
4. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. PMID: 21668043
5. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. PMID: 22495074
6. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
7. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. 2001;142(12):5182-5189. PMID: 11713213
8. Mangili A, Falutz J, Mamputu JC, et al. Predictors of treatment response to tesamorelin in HIV-infected patients with excess abdominal fat. PLoS One. 2015;10(10):e0140358. PMID: 26457580
9. Egrifta WR (Tesamorelin) FDA Prescribing Information, 2025
10. Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf

---

Related Reading

• Fat Burning Peptides Explained
• Peptides for Body Recomposition
• How to Reconstitute Peptides